Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference
…
56,035€
0,83%
Echtzeit-Aktienkurs Bristol-Myers Squibb Co.
Bid:
Ask:
Nachrichten zur Bristol-Myers Squibb Co. Aktie
Bristol Myers Squibb wins antitrust case against insurers regarding generics
…
Analyst Report: Bristol-Myers Squibb Co.
…
Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
…
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974 (“ERISA”) (Brower Piven Release)
BALTIMORE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Lawsuits have been filed alleging that a number of large…
Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
…
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult…
Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
…
Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
…
Biotech Reveals More From The Study That Boosted Shares 83%
The company is hoping to take on Bristol Myers Squibbs Camzyos, a treatment for obstructive HCM.…
Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma
The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake,…
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock.…
If Youd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Heres How Much Youd Have Today
The answer isnt great, but theres still reason to like Bristol Myers Squibb.…
Bristol-Myers Squibb: A Lost Decade?
…
Neue Analysteneinschätzung - Carbon Done Right Developments, Bristol Myers Squibb, Deutsche Lufthansa Aktie
Negative Wirtschaftsdaten aus den USA belasteten zuletzt die Indizes. Das abschwächende Wirtschaftswachstum in den USA, wie auch die anhaltende Inflation…
Pfizer: Doppelschlag vor den Zahlen – das wird erwartet
Mit Eli Lilly und Merck & Co haben bereits zwei große amerikanische Pharma-Konzerne überzeugende Ergebnisse vorgelegt. Bristol-Myers Squibb hingegen patzte…
Bristol Myers Squibb: Tough Times Continue
…
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality…
Bristol-Myers Squibb: Pharmagigant will die Kosten massiv drücken - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…
Bristol-Myers Squibb: Aktie im freien Fall – das steckt dahinter
Bristol Myers Squibb enttäuschte mit den Zahlen für das erste Quartal.…
Bristol Myers Squibb: Aktie bricht nach Zahlen massiv ein – jetzt günstig einsteigen?
Der amerikanische Pharma-Konzern Bristol Myers Squibb hat mit seinen Zahlen zum ersten Quartal für Ernüchterung gesorgt. Nach der Bekanntgabe der…
Bristol Myers Squibb: Aktie bricht nach Zahlen massiv ein – jetzt günstig einsteigen?
Der amerikanische Pharma-Konzern Bristol Myers Squibb hat mit seinen Zahlen zum ersten Quartal für Ernüchterung gesorgt. Nach der Bekanntgabe der…
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
…
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2024.…
Is Bristol Myers Squibb Stock a Millionaire Maker?
Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.…
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda…
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.…
Bristol-Myers Squibb stock slips despite earnings beat By Investing.com
Bristol-Myers Squibb stock slips despite earnings beat…
Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates By Investing.com
Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates…
Bristol Myers posts quarterly loss, revenue rises 5%
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio…
Pharmabranche: Neuer Novartis-Chef kommt von Bristol Myers Squibb
Jörg Reinhardt tritt nach zwölf Jahren als Novartis-Chef zurück. Sein Nachfolger steht bereits fest. Er kommt von einem direkten Konkurrenten.…
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…
Is Bristol Myers Squibb A Buy At These Bottom Levels?
…
Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies By Reuters
Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies…
Got $500? 3 Healthcare Stocks to Buy and Hold Forever @themotleyfool #stocks $ISRG $BMY $NVO
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…
Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72%
The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell…
Biotech im Visier - Bristol-Myers Squibb, Formycon, MorphoSys, Vidac Pharma Aktie
Für viele Pharma- und Biotechaktionäre hat dieser Sektor einen ganz besonderen Charme. In dieser hochspekulativen Branche liegen Erfolg und Misserfolg…
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF? @themotleyfool #stocks $BMY $LLY $^GSPC $NVO $VOO
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…
Global Chemotherapy Market Size To Exceed USD 16.2 Billion By 2033 | CAGR of 6.54%
The Global Chemotherapy Market Size was Valued at USD 8.6 Billion in 2023 and the Worldwide Chemotherapy Market Size is…
Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
…
Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen
87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen
87 Prozent, 97 Prozent und 105 Prozent - diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen
87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Bristol Myers Squibb: The Comeback Is Unfolding
…